# Exelixis, Inc. (EXEL): MoatMap facts

As of 14 Oct 2026. Research data, not investment advice.

As of 14 Oct 2026, MoatMap's StockRank for Exelixis, Inc. (EXEL) is 98/100, ranked against 24,000+ stocks in 35 markets (Quality 89, Value 49, Momentum 76, each scored against its sector).

- StockRank: 98/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 89, Value 49, Momentum 76: each a 0-100 percentile within the stock's sector.
- Position: #445 overall, #58 in Healthcare.
- Listing: United States, NMS; Healthcare / Biotechnology.
- Last close: 59.82 USD on 12 Oct 2026.
- Insider filings, last 180 days: directors sold USD 7.1M.
- Buybacks, last 180 days: the company bought back USD 1.3B on 2 days.

Source: https://moatmap.ai/stock/EXEL
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker